Menu Search
Equities

China Biotech Services Holdings Ltd

2LL4:BER

China Biotech Services Holdings Ltd

Actions
  • Price (EUR)0.0195
  • Today's Change-0.001 / -2.50%
  • Shares traded1.01k
  • 1 Year change-47.30%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year China Biotech Services Holdings Ltd's revenues fell -88.55% from 1.85bn to 211.99m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 258.09m to a loss of 95.45m.
Gross margin-48.50%
Net profit margin-384.55%
Operating margin-383.18%
Return on assets-31.11%
Return on equity-31.00%
Return on investment-45.60%
More ▼

Cash flow in HKDView more

In 2023, cash reserves at China Biotech Services Holdings Ltd fell by 20.68m. However, the company earned 195.19m from its operations for a Cash Flow Margin of 92.08%. In addition the company used 67.53m on investing activities and also paid 146.17m in financing cash flows.
Cash flow per share-0.1171
Price/Cash flow per share--
Book value per share0.4051
Tangible book value per share0.2417
More ▼

Balance sheet in HKDView more

China Biotech Services Holdings Ltd has a Debt to Total Capital ratio of 30.44%, a higher figure than the previous year's 11.08%.
Current ratio0.7427
Quick ratio0.715
Total debt/total equity0.4276
Total debt/total capital0.3044
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.